Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman Salt Lake City, UT – (Globe Newswire – November 19, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief Executive Officer in fulfillment of its goal to attract and secure a…
Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease Cocrystal Lithium-Based Therapy, “LiProSal™” Targets the Reduction of Agitation in Patients with AD Salt Lake City, UT – (Globe Newswire – October 29, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of…
USF Researcher Develops Therapeutic Vaccine to Combat Alzheimer’s Disease and Neurodegenerative Disorders
Alzamend Neuro™ has licensed the USF treatment to help advance commercialization
TAMPA, Fla. – A neuroscientist at the USF Health Byrd Alzheimer’s Institute and the USF College of Pharmacy has developed an immunotherapeutic treatment now undergoing testing for the prevention, treatment and cure of Alzheimer’s disease as well as other neurological disorders. This innovative technology has been exclusively licensed from USF to Alzamend Neuro™, Inc.
Chuanhai Cao, a USF associate professor of pharmaceutical sciences and a researcher at the USF Health Byrd Alzheimer’s Institute, has focused his research on peptides for use as a vaccine for Alzheimer’s disease and other neurological diseases.
Dr. Cao has developed an antigen activated immune cell-based vaccine that shows promise in helping combat nervous system dysfunctions in Alzheimer’s disease. Research has shown that the therapeut..
SALT LAKE CITY, Jan. 09, 2017 (GLOBE NEWSWIRE) — Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today Willie Aames will serve as its International Spokesperson while joining the team as Creative Advisor. The Company stated that with its recent launch of its Regulation A+ Tier II Offering online at www.AlzamendRegA.com™, it looks forward to the many contributions, inspiration and leadership that Aames will provide. With the Company’s campaign targeted to raise $50MM in new equity capital in less than a full year and able to take investment immediately, the addition of Aames is strategic and notable. On December 8, 2016, the Company was notified by the SEC that it had qualified its Form 1-A Application allowing the Company to move forward with the Offering which will leverage the key component of the Reg. A+ Tier II rules which allow for the solicitation of the general public as well as traditional investors and financial institutions.
Photos accompanying this announcement..
The University of South Florida was granted a patent related to this technology (USPTO # 8,188,046) in 2012, and this patent is exclusively licensed to Alzamend Neuro, a Utah-based pharmaceutical technology company that is dedicated to finding a prevention, treatment and cure for Alzheimer’s disease. The company’s goal is to move this technology out of the research and preclinical stage and into a path toward commercialization.
LINK to Press Release
The post Licenses Patented Alzheimer’s Vaccine appeared first on Alzamend.
Alzamend Neuro, Inc. was qualified by the SEC as of December 8th to generally solicit and crowdfund up to $50 million dollars of equity from the general public, accredited investors, and institutional investors, to support its strategic plans, through general solicitation and traditional mechanisms.
The post Qualified for Reg A+ appeared first on Alzamend.
Alzamend Neuro, Inc. CEO, Phil Mansour, will present as a part of a panel of on December 12th atBio Florida 2016, in Jacksonville, Florida, on the process, pros and cons of Reg A+.
The post BioFlorida 2016 appeared first on Alzamend.